AI assistant
Celularity Inc — Director's Dealing 2024
Feb 22, 2024
34506_dirs_2024-02-21_06bdc7ae-b575-4467-b171-bef660245e48.zip
Director's Dealing
Open in viewerOpens in your device viewer
SEC Form 4 — Statement of Changes in Beneficial Ownership
Issuer: Celularity Inc (CELU)
CIK: 0001752828
Period of Report: 2024-02-16
Reporting Person: Kilcoyne Adrian (Chief Medical Officer)
Non-Derivative Transactions
| Date | Security | Code | Shares | Price | A/D | Holdings After | Ownership |
|---|---|---|---|---|---|---|---|
| 2024-02-17 | Class A Common Stock | F | 52762 | $0.434 | Disposed | 1122238 | Direct |
Derivative Transactions
| Date | Security | Exercise Price | Code | Shares | A/D | Expiration | Underlying | Ownership |
|---|---|---|---|---|---|---|---|---|
| 2024-02-16 | Stock Option Grant (Right to Buy) | $0.4340 | A | 205213 | Acquired | 2034-02-15 | Class A Common Stock (205213) | Direct |
Footnotes
F1: Represents shares withheld by the Issuer to satisfy the Reporting Person's tax obligations associated with the vesting and settlement of restricted stock units ("RSUs") granted under the Celularity Inc. 2021 Equity Incentive Plan (the "2021 Plan") and does not represent a sale.
F2: Reflects shares underlying RSUs subject to vesting.
F3: The option was granted pursuant to the 2021 Plan. The shares underlying such option will vest in equal quarterly installments during 2024 such that 25% of the option will vest on each of March 31, 2024, June 30, 2024, September 30, 2024 and December 31, 2024, subject to the Reporting Person's continuous service with the Issuer through each such date.